Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
December 12, 2022 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and...
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
December 10, 2022 15:00 ET
|
Affimed N.V.
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL) patients with a differentiated safety profile AFM13...
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
December 10, 2022 14:20 ET
|
Affimed N.V.
AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patientsPatients had...
Persbericht Biocartis Group NV: Openbaarmaking van transparantiekennisgevingen
December 09, 2022 11:40 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE9 december 2022, 17:40 CET Openbaarmaking van transparantiekennisgevingen Mechelen, België, 9 december 2022 – Biocartis Group NV (de...
Press release Biocartis Group NV: Disclosure of transparency notifications
December 09, 2022 11:40 ET
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION 9 December 2022, 17:40 CET Disclosure of transparency notifications Mechelen,...
CURE Media Group announces winners of the 2022 MPN Heroes Recognition Program
December 09, 2022 11:00 ET
|
CURE Media Group
CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients,...
Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
December 08, 2022 12:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
December 08, 2022 02:00 ET
|
iOnctura
Geneva, Switzerland, 8 December 2022 -- iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways,...
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
December 07, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
December 07, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...